TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade

Advances in Cancer Research

Volumn 110, Issue , 2011, Pages 107-139

  Soussi, Thierry ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Epidemiology; Missense; Mutation; Reassessment; Sequencing; Synonymous

Indexed keywords

PROTEIN P53;

ARTIFACT; BOOK; CANCER GENETICS; GENETIC DATABASE; GENETIC HETEROGENEITY; GENOME ANALYSIS; HUMAN; LOSS OF FUNCTION MUTATION; MOLECULAR EPIDEMIOLOGY; PENETRANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PUBLICATION; QUALITY CONTROL;

EID: 79959428081     PISSN: 0065230X     EISSN: 0065230X     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386469-7.00005-0     Document Type: Chapter

References (116)

1. Aas T., Borresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E., et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996, 2:811-814.
2. Baker S.J., Fearon E.R., Nigro J.M., Hamilton S.R., Preisinger A.C., Jessup J.M., et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244:217-221.
3. Bargonetti J., Manfredi J.J., Chen X., Marshak D.R., Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 1993, 7:2565-2574.
4. Baudot A., Real F.X., Izarzugaza J.M., Valencia A. From cancer genomes to cancer models: Bridging the gaps. EMBO Rep. 2009, 10:359-366.
5. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402.
6. Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T. Analysis of p53 mutation status in human cancer cell lines: A paradigm for cell line cross-contamination. Cancer Biol. Ther. 2008, 7:699-708.
7. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485.
8. Brachmann R.K., Yu K., Eby Y., Pavletich N.P., Boeke J.D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 1998, 17:1847-1859.
9. Brash D.E., Rudolph J.A., Simon J.A., Lin A., McKenna G.J., Baden H.P., et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10124-10128.
10. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
11. Broz D.K., Attardi L.D. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 2010, 31:1311-1318.
12. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14338-14342.
13. Campbell I.G., Qiu W., Polyak K., Haviv I. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 2008, 358:1634-1635. author reply, 1636.
14. Chipuk J.E., Green D.R. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006, 13:994-1002.
15. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265:346-355.
16. Claustres M., Horaitis O., Vanevski M., Cotton R.G. Time for a unified system of mutation description and reporting: A review of locus-specific mutation databases. Genome Res. 2002, 12:680-688.
17. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., et al. Interhelical angles in the solution structure of the oligomerization domain of p53: Correction. Science 1995, 267:1515-1516.
18. Collavin L., Lunardi A., Del Sal G. p53-family proteins and their regulators: Hubs and spokes in tumor suppression. Cell Death Differ. 2010, 17:901-911.
19. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274:430-432.
20. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 1999, 19:1438-1449.
21. DiGiammarino E.L., Lee A.S., Cadwell C., Zhang W., Bothner B., Ribeiro R.C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 2002, 9:12-16.
22. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
23. Donehower L.A., Lozano G. 20years studying p53 functions in genetically engineered mice. Nat. Rev. Cancer 2009, 9:831-841.
24. Feldmeyer N., Schmeiser H.H., Muehlbauer K.R., Belharazem D., Knyazev Y., Nedelko T., et al. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat. Res. 2006, 608:163-168.
25. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., et al. Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005, 7:363-373.
26. Forbes S.A., Tang G., Bindal N., Bamford S., Dawson E., Cole C., et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010, 38:D652-D657.
27. Friedlander P., Haupt Y., Prives C., Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 1996, 16:4961-4971.
28. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990, 9:1595-1602.
29. Goh H.S., Yao J., Smith D.R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995, 55:5217-5221.
30. Gorina S., Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996, 274:1001-1005.
31. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
32. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
33. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12129-12134.
34. Haber D.A., Settleman J. Cancer: Drivers and passengers. Nature 2007, 446:145-146.
35. Halevy O., Michalovitz D., Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990, 250:113-116.
36. Hamroun D., Kato S., Ishioka C., Claustres M., Beroud C., Soussi T. The UMD TP53 database and website: Update and revisions. Hum. Mutat. 2006, 27:14-20.
37. Harris S.L., Levine A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
38. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 1995, 9:305-311.
39. Hofseth L.J., Robles A.I., Yang Q., Wang X.W., Hussain S.P., Harris C. p53: At the crossroads of molecular carcinogenesis and molecular epidemiology. Chest 2004, 125:83S-85S.
40. Hollstein M., Marion M.J., Lehman T., Welsh J., Harris C.C., Martel-Planche G., et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994, 15:1-3.
41. Holmila R., Fouquet C., Cadranel J., Zalcman G., Soussi T. Splice mutations in the p53 gene: Case report and review of the literature. Hum. Mutat. 2003, 21:101-102.
42. Horaitis O., Cotton R.G. The challenge of documenting mutation across the genome: The human genome variation society approach. Hum. Mutat. 2004, 23:447-452.
43. Hussain S.P., Raja K., Amstad P.A., Sawyer M., Trudel L.J., Wogan G.N., et al. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12770-12775.
44. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., Kaelin W.G.J. Chemosensitivity linked to p73 function. Cancer Cell 2003, 3:403-410.
45. Iwabuchi K., Bartel P.L., Li B., Marraccino R., Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6098-6102.
46. Joerger A.C., Fersht A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77:557-582.
47. Junttila M.R., Evan G.I. p53-A Jack of all trades but master of none. Nat. Rev. Cancer 2009, 9:821-829.
48. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
49. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8424-8429.
50. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991, 252:1708-1711.
51. Khoury M.P., Bourdon J.C. The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol. 2010, 2:a000927.
52. Krizhanovsky V., Lowe S.W. Stem cells: The promises and perils of p53. Nature 2009, 460:1085-1086.
53. Kubbutat M.H., Ludwig R.L., Ashcroft M., Vousden K.H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 1998, 18:5690-5698.
54. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
55. Leu J.I., Dumont P., Hafey M., Murphy M.E., George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6:443-450.
56. Levine A.J., Oren M. The first 30years of p53: Growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
57. Lin J., Chen J., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994, 8:1235-1246.
58. Liu Z., Muehlbauer K.R., Schmeiser H.H., Hergenhahn M., Belharazem D., Hollstein M.C. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res. 2005, 65:2583-2587.
59. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K., et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 2004, 36:63-68.
60. Luo J.L., Tong W.M., Yoon J.H., Hergenhahn M., Koomagi R., Yang Q., et al. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res. 2001, 61:8158-8163.
61. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: A new biomedical research tool. Oncogene 2001, 20:320-328.
62. Mardis E.R. Next-generation DNA sequencing methods. Annu. Rev. Genom. Hum. Genet. 2008, 9:387-402.
63. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000, 25:47-54.
64. Marrogi A.J., Khan M.A., van Gijssel H.E., Welsh J.A., Rahim H., Demetris A.J., et al. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J. Natl. Cancer Inst. 2001, 93:1652-1655.
65. McLendon R., Friedman A., Bigner D., Van Meir E.G., Brat D.J., Mastrogianakis M., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
66. Menendez D., Inga A., Resnick M.A. The expanding universe of p53 targets. Nat. Rev. Cancer 2009, 9:724-737.
67. Metzker M.L. Sequencing technologies-The next generation. Nat. Rev. Genet. 2010, 11:31-46.
68. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11:685-696.
69. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990, 62:671-680.
70. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11:577-590.
71. Milner J. Flexibility: The key to p53 function?. Trends Biochem. Sci. 1995, 20:49-51.
72. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
73. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
74. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994, 13:3496-3504.
75. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 2007, 357:2543-2551.
76. Pavletich N.P., Chambers K.A., Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993, 7:2556-2564.
77. Pinto E.M., Billerbeck A.E., Villares M.C., Domenice S., Mendonca B.B., Latronico A.C. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metab. 2004, 48:647-650.
78. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
79. Poyurovsky M.V., Katz C., Laptenko O., Beckerman R., Lokshin M., Ahn J., et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat. Struct. Mol. Biol. 2010, 17:982-989.
80. Puisieux A., Lim S., Groopman J., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991, 51:6185-6189.
81. Raycroft L., Wu H.Y., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990, 249:1049-1051.
82. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9330-9335.
83. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
84. Roukos D.H. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 2008, 358. author reply, 1636.
85. Saller E., Tom E., Brunori M., Otter M., Estreicher A., Mack D.H., et al. Increased apoptosis induction by 121F mutant p53. EMBO J. 1999, 18:4424-4437.
86. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 2001, 8:781-794.
87. Schadt E.E., Linderman M.D., Sorenson J., Lee L., Nolan G.P. Computational solutions to large-scale data management and analysis. Nat. Rev. Genet. 2010, 11:647-657.
88. Shimizu H., Burch L.R., Smith A.J., Dornan D., Wallace M., Ball K.L., et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 2002, 277:28446-28458.
89. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
90. Sot B., Freund S.M., Fersht A.R. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J. Biol. Chem. 2007, 282:29193-29200.
91. Soussi T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep 2010, 11:822-826.
92. Soussi T., Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 2001, 1:233-240.
93. Soussi T., Beroud C. Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 2003, 21:192-200.
94. Soussi T., Caron de Fromentel C., Sturzbecher H.W., Ullrich S., Jenkins J., May P. Evolutionary conservation of the biochemical properties of p53: Specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70. J. Virol. 1989, 63:3894-3901.
95. Soussi T., Dehouche K., Beroud C. p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum. Mutat. 2000, 15:105-113.
96. Soussi T., Ishioka C., Claustres M., Beroud C. Locus-specific mutation databases: Pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 2006, 6:83-90.
97. Soussi T., Kato S., Levy P.P., Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 2005, 25:6-17.
98. Soussi T., Lozano G. p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. 2005, 331:834-842.
99. Soussi T., Wiman K.G. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007, 12:303-312.
100. Soussi Zander C., Soussi T. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 2008, 358:1635. author reply, 1636.
101. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. 2003, 21:201-216.
102. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 2005, 37:590-592.
103. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999, 18:1660-1672.
104. Takahashi T., Nau M.M., Chiba I., Birrer M.J., Rosenberg R.K., Vinocour M., et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-494.
105. Thukral S.K., Blain G.C., Chang K.K., Fields S. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2. Mol. Cell. Biol. 1994, 14:8315-8321.
106. Tong W.M., Lee M.K., Galendo D., Wang Z.Q., Sabapathy K. Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int. J. Cancer 2006, 119:745-749.
107. Tornaletti S., Rozek D., Pfeifer G.P. The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 1993, 8:2051-2057.
108. Toyooka S., Tsuda T., Gazdar A.F. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 2003, 21:229-239.
109. Varley J.M., Attwooll C., White G., McGown G., Thorncroft M., Kelsey A.M., et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001, 20:2647-2654.
110. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
111. Wang Y., Reed M., Wang P., Stenger J.E., Mayr G., Anderson M.E., et al. p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes Dev. 1993, 7:2575-2586.
112. Wang Z., Shen D., Parsons D.W., Bardelli A., Sager J., Szabo S., et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166.
113. Yang A., McKeon F. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell Biol. 2000, 1:199-207.
114. Zalcman G., Bergot E., Hainaut P. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 2008, 358:1635. author reply, 1636.
115. Ziebolz B., Droege M. Toward a new era in sequencing. Biotechnol. Annu. Rev. 2007, 13:1-26.
116. Zupnick A., Prives C. Mutational analysis of the p53 core domain L1 loop. J. Biol. Chem. 2006, 281:20464-20473.